Acute Radiation Syndrome
SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Efficacy Rule.
We are proud of SNBL’s long history of excellence and leadership across our multiple product and service offerings; but more importantly, we benchmark our true success by what we achieve for our customers today and what we do to enable a better future for patients and their families tomorrow.Read More
SNBL USA is committed to providing clients with quality you expect with your preclinical needs. We are committed to providing service you trust with the turnaround you need.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
Everett, WA – June 25, 2015 – SNBL USA, the experts in preclinical research, today announced Monica Vegarra has joined the executive team to serve in the newly created role of Director of Toxicology Support Services. In this position Monica will assume leadership for the husbandry, specimen management and specimen shipping teams, drive strategic plans, policies, and procedures while ensuring the quality and integrity of the data generated by SNBL USA. “We are fortunate to have Monica on board as this role represents our commitment in strengthening SNBL USA as a leading, innovative...Read More
SNBL USA will be at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting this week in New Orleans. If you are attending ASGCT, the largest gene and cell therapy conference in the world, stop by booth #124. That is where we will be showcasing the molecular biology and stem cell services we offer to support gene therapy studies. See you in New Orleans! American Society of Gene & Cell Therapy 18th Annual Meeting...Read More
Pre-SOT Abstract: Blood urea nitrogen (BUN) and creatinine (CRN) have been used as biomarkers (BMs) for detecting drug-induced renal toxicities. Since FDA and EMA proposed several BMs in rats, such as urinary protein, albumin (ALB), β2-microglobulin (B2M), clusterin (CLU) and cystatin C (CysC), we examined the availability of these urinary BMs in cynomolgus monkeys. We used 3 renal toxic compounds: gentamicin (GM), cisplatin (CDDP) and puromycin aminonucleoside (PAN). Three cynomolgus monkeys/group (total 9 animals) received GM (sc, 40 mg/kg/day, 7 days), CDDP (iv, 3 mg/kg, single dose) or...Read More